I've brought this up every other week, got tired of repeating it, but we are at the point where reference viruses / spike proteins used for these vaccines and therapeutics may be outdated as active hosts have seen a massive increase... Opportunities for variation in transmission and lethality are increasing as well. Only one strategy remains agnostic to virus mutations, and that is immune modulation.

And only one therapeutic appears ideally suited for immune modulation. Leronlimab.